Company Overview
Company Type: Public Company
Website: lexariabioscience.com
Number of Employees: 7
Ticker: LEXX (NasdaqCM)
Year Founded: 2004


Business Description
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company’s DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.5
Market Capitalization
11.7
TEV/Total Revenue
14.4x
EBITDA
(9.4)
Total Enterprise Value
6.8
TEV/EBITDA
NM
EBIT
(9.6)
Cash & ST Invst.
4.7
P/Diluted EPS Before Extra
NM
Net Income
(9.5)
Total Debt
0.2
Price/Tang BV
2.0x
Capital Expenditure
0.0
Total Assets
7.2
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of May-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Aug-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.23)
-
(1.41)
(0.91)
(1.03)
Revenue (mm)
0.12
0.00
0.44
0.70
0.12

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
14.64x

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
9.62
Potential Upside
660.87%


Key Professionals
Name
Title
Bunka, Christopher A.
Chairman & CEO
Docherty, John M.
President & Director
Shankman, Mike 
Chief Financial Officer
Hamilton, Kristin 
Director of Operations
Carle, Vanessa 
Head of Legal
Ainslie, Philip N.
Advisor & Consultant

Key Board Members
Name
Title
Bunka, Christopher A.
Chairman & CEO
Docherty, John M.
President & Director
Ainslie, Philip N.
Advisor & Consultant
Baxter, Nicholas W.
Independent Director
Gangolli, Julian S.
Strategic Advisor
McKechnie, William Edward
Independent Director
Reese, Albert L.
Independent Director
Turkel, Catherine C.
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
740 McCurdy Road Suite 100 | Kelowna, BC | V1X 2P7 | Canada
Phone: 250-765-6424   

Current and Pending Investors
Anson Group, Brio Capital L.P., CAB Financial Services Ltd., CVI Investments, Inc., Empery Asset Management, LP, GS Venture Partners LLC, Intracoastal Capital LLC, Iroquois Capital Management, LLC, Key Investment Partners LLC, Kingsbrook Partners LP, L1 Capital Pty. Limited, Odlum Brown Limited, Triple K Ventures Ltd

Prior Investors
Enertopia Corp. (OTCPK:ENRT)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 1.26
Market Cap (mm)
11.4
Open
 1.37
Shares Out. (mm)
9.0
Previous Close
 1.26
Float %
72.6%
Change on Day
(0.04)
Shares Sold Short (mm)
0.4
Change % on Day
(3.2)%
Dividend Yield %
-
Day High/Low
 1.37/ 1.24
Diluted EPS Excl. Extra Items
(1.56)
52 wk High/Low
 4.94/ 0.89
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.09
Beta 5Y
0.95


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)


Index Membership
S&P Completion Index (CI);S&P TMI Index;S&P Completion Index (CI) Health Care (US Dollar);S&P TMI Health Care


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
ViPova Tea
Poppy's Teas LLC produces cannabinoid infused teas. The company was founded in 2014 and is based in St Augustine, Florida. As of December 12, 2014, Poppy's Teas LLC operates as a subsidiary of Lexaria Corp.

United States and Canada
Soft Drinks and Non-alcoholic Beverages
-
-
-
Palmetto Point Property, Mississippi
Palmetto Point Property, Mississippi comprises oil and gas exploration property located in Mississippi.

United States and Canada
Oil and Gas Exploration and Production
-
-
-
Griffin & Griffin Exploration, LLC, Mississippi Area of Mutual Interest
Griffin & Griffin Exploration, LLC, Mississippi Area of Mutual Interest consists of crude oil and natural gas reserve and includes 50 prospective oil wells. The property is located in Mississippi.

United States and Canada
Oil and Gas Exploration and Production
-
-
-
Belmont Lake field in Mississippi
10 Oil and Gas Wells consist of 10 wells engaged in oil and natural gas production activities. The wells are based in Mississippi.

United States and Canada
Oil and Gas Exploration and Production
-
-
-
Certain Producing Oil Assets Within Wilkinson County, Mississippi
Certain Producing Oil Assets Within Wilkinson County, Mississippi comprises four oil producing wells and reserves and is located in Mississippi.

United States and Canada
Oil and Gas Exploration and Production
-
-
-
Great Lakes Cannabis Corp

United States and Canada
-
-
-
-
Lexaria Canpharm Corp.
Lexaria Canpharm Corp. develops novel psychotropic cannabinoid formulations for potential commercialization. The company was incorporated in 2019 and is based in Kelowna, Canada. Lexaria Canpharm Corp. operates as a subsidiary of Lexaria Bioscience Corp.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-29-2023
Oct-3-2023
Public Offering
Target
Lexaria Bioscience Corp. (NasdaqCM:LEXX)


1.57
May-08-2023
-
Private Placement
Target
Lexaria Bioscience Corp. (NasdaqCM:LEXX)


0.25
Apr-3-2023
May-9-2023
Public Offering
Target
Lexaria Bioscience Corp. (NasdaqCM:LEXX)


2.00
Aug-12-2022
-
Public Offering
Target
Lexaria Bioscience Corp. (NasdaqCM:LEXX)


5.93
Jan-28-2022
-
Shelf Registration
Target
Lexaria Bioscience Corp. (NasdaqCM:LEXX)


50.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Follow-on Equity Offerings
Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $1.56978 million.
Sep-29-2023
Follow-on Equity Offerings
Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $1.56978 million.
Sep-21-2023
Product-Related Announcements
Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1
Sep-07-2023
End of Lock-Up Period
Certain Common Stock of Lexaria Bioscience Corp. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.
Sep-07-2023
End of Lock-Up Period
Certain Stock Options of Lexaria Bioscience Corp. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.

M&A Advisors
Macdonald Tuskey, W.L. Macdonald Law Corporation


Advisors
Most Recent Auditor
Davidson & Company LLP
M&A Advisors
Macdonald Tuskey, W.L. Macdonald Law Corporation
Private Placement Advisors
Echelon Wealth Partners Inc., Haywood Securities Inc., Macdonald Tuskey, Sichenzia Ross Ference LLP, The Special Equities Group, LLC, VIII Capital Corp.
Public Offering Advisors
Davidson & Company LLP, Macdonald Tuskey, Maxim Group LLC, MNP LLP, Sichenzia Ross Ference LLP


Most Recent Auditor
Davidson & Company


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
ValuEngine, Inc.

Oct 02, 2023 04:50 AM
LEXX
ValuEngine Rating and Forecast Report for LEXX
Reports
11
MarketLine

Sep 20, 2023 06:01 AM
LEXX
Lexaria Bioscience Corp
Reports
43
Zacks Small-Cap Research
Vandermosten, John D.
Aug 28, 2023 07:01 AM
LEXX
LEXX: 3Q:23 Financial Results & Corporate Updates
Reports
14
Pechala's Reports

Aug 04, 2023 11:00 PM
LEXX
LEXARIA BIOSCIENCE EQUITY WARRANT 12 JAN (LEXXW=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2
Pechala's Reports

Aug 04, 2023 11:00 PM
LEXX
LEXARIA BIOSCIENCE CORP COMMON (LEXX=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2
Maxim Group
Okunewitch, Michael
Aug 02, 2023 01:11 PM
LEXX
DehydraTECH CBD Pipeline Advancing with Second Human Clinical Program Planned for Diabetes
Reports
6
Maxim Group
Okunewitch, Michael
Jul 28, 2023 11:10 AM
LEXX
Newly-Formed Subsidiary Highlights Potential for CPG Pipeline Expansion; Nicotine Study Data Approaching in Coming Weeks
Reports
6
Maxim Group
Okunewitch, Michael
Jul 21, 2023 05:37 AM
LEXX
DehydraTECH Technology Platform is a Game Changer for CBD, Nicotine, and More – Initiating with a Buy Rating and $2.00 PT
Initiation of Coverage*
27
Zacks Small-Cap Research
Vandermosten, John D.
Jun 26, 2023 07:01 AM
LEXX
LEXX: A Little Bit of Everything
Reports
12
Zacks Small-Cap Research
Vandermosten, John D.
Apr 20, 2023 07:01 AM
LEXX
DehydraTECH CBD May Offer New Mechanism of Action
Reports
12


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Invenomic Capital Management LP

766,573

8.54

1.1

Jun-30-2023


Jackler, Don 

468,382

5.22

0.6

Aug-14-2023


Boos, Wayne W.

450,000

5.01

0.6

Sep-07-2023


Bunka, Christopher A.

273,543

3.05

0.4

Aug-14-2023


CAB Financial Services Ltd.

254,412

2.83

0.3

Aug-14-2023


Docherty Management Ltd.

54,075

0.60

0.1

Aug-14-2023


Geode Capital Management, LLC

48,837

0.54

0.1

Jun-30-2023


The Vanguard Group, Inc.

33,329

0.37

0.0

Jun-30-2023


Susquehanna International Group, LLP, Asset Management Arm

15,426

0.17

0.0

Jun-30-2023


McKechnie B.A., William Edward

13,191

0.15

0.0

Aug-14-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Boos, Wayne W.
450,000
450,000
Invenomic Capital Management LP
766,573
293,470
Tower Research Capital LLC
10,951
6,862
Blackstone Alternative Investment Advisors LLC
0
300
Wells Fargo & Company, Private Banking and Investment Banking Arm
38
2

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Susquehanna International Group, LLP, Asset Management Arm
15,426
(52,026)
Dimensional Fund Advisors LP
0
(15,268)
Jackler, Don 
468,382
(12,200)
Centiva Capital, LP
0
(12,059)
UBS Asset Management AG
99
(4,540)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Cashew Berry Date protein-energy Bars, Chocolate Berry Date Bars, ChrgD+, DehydraTECH, dem-a22-1 (Future), DIAB-A22-1, epil-a21-1 (Future), Hemp Seed Products, hyper-h21-4 (Future), Lexaria Energy, Licensing of DehydraTECH, Natural Gas, Natural Gas Liquids, nic-h22-1 (Future), Protein Energy Bars, Skin Cream Products (Future), TurboCBD, Zero-Sugar Cannabinoid /Pterostilbene Edible Tablet


Upcoming Events
Date/Time
Type
Oct-10-2023 1:00 PM (PST)
Shareholder/Analyst Calls
Oct-10-2023
Special/Extraordinary Shareholders Meeting
Nov-28-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEDAR
Material Change Report
499 KB
Oct-03-2023
Sep-28-2023
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEC
8-K (1.01, 3.02, 9.01)
817 KB
Oct-02-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEC
424B5
367 KB
Sep-29-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEDAR
News Releases
138 KB
Sep-21-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEDAR
News Releases
211 KB
Sep-21-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
RNS
Non Regulatory Announcement
22 KB
Aug-30-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEDAR
News Releases
192 KB
Aug-28-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEDAR
Material Change Report
46 KB
Aug-28-2023
Aug-24-2023
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEC
8-K (8.01)
141 KB
Aug-23-2023
-
Lexaria Bioscience Corp. (NasdaqCM:LEXX)
SEDAR
Management Proxy Materials
146 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Turkel MBA, Ph.D., PharmD, Catherine C. (Independent Director)
Feb-09-2023
Common Shares
1,500
5,862
Open Market Acquisition
New
Form 4
Downey CMA, CPA, Gregory John (Former CFO & Treasurer)
Oct-14-2022
Common Shares
121
347
Private Acquisition
6.60
Form 4
CAB Financial Services Ltd.
Oct-12-2022 - Oct-13-2022
Common Shares
38,500
107,698
Open Market Acquisition
17.83
Form 4
-
Oct-12-2022
Common Shares
21,900
59,809
Open Market Acquisition
-
Form 4
-
Oct-13-2022
Common Shares
16,600
47,889
Open Market Acquisition
-
Form 4
Reese Jr., Albert L. (Independent Director)
May-24-2022
Common Shares
5,000
13,449
Other Acquisition
84.50
Form 4
Reese Jr., Albert L. (Independent Director)
May-20-2022
Common Shares
1,799
4,960
Other Acquisition
43.69
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bunka, Christopher A.
Chairman & CEO
1-250-765-6424
(250) 765-2599
cbunka@lexariabioscience.com
Docherty, John M.
President & Director
250-765-6424
-

Ainslie, Philip N.
Advisor & Consultant
250-765-6424
-

Baxter, Nicholas W.
Independent Director
250-765-6424
-

Gangolli, Julian S.
Strategic Advisor
250-765-6424
-

McKechnie, William Edward
Independent Director
250-765-6424
-

Reese, Albert L.
Independent Director
250-765-6424
-

Turkel, Catherine C.
Independent Director
250-765-6424
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bunka, Christopher A.
Chairman & CEO
1-250-765-6424
(250) 765-2599
cbunka@lexariabioscience.com
Docherty, John M.
President & Director
250-765-6424
-

Shankman, Mike 
Chief Financial Officer
250-765-6424
-

Hamilton, Kristin 
Director of Operations
250-765-6424
-
khamilton@lexariabioscience.com
Carle, Vanessa 
Head of Legal
250-765-6424
-
vcarle@lexariabioscience.com
Ainslie, Philip N.
Advisor & Consultant
250-765-6424
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
